Position in SLGL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,668,150
New position
Shares Held
22,500
first reported quarter
Ownership
0.687%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#8
of 24 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026GILDER GAGNON HOWE & CO LLC holds $353,222,516 across 21 Biotechnology names. SLGL ranks #17 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
269,051 | $80,992,422 | |
| 2 | NKTR |
Nektar Therapeutics
|
600,873 | $41,946,944 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
548,926 | $40,884,008 | |
| 4 | ARQT |
Arcutis Biotherapeutics, Inc.
|
1,313,211 | $34,432,392 | |
| 5 | CYTK |
Cytokinetics Inc
|
400,245 | $34,096,871 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
229,053 | $26,265,507 | |
| 7 | QURE |
uniQure N.V.
|
530,979 | $24,456,892 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
28,573 | $15,342,272 |
All Filings in SLGL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,668,150 | 22,500 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||